This issue of CMAJ includes two commentaries decrying the suppression of data concerning unsafe or ineffective medication.
Jane Garland, a psychiatrist, clinical researcher and past investigator in SSRI trials, states that negative results from SSRI trials go unpublished, while the published evidence to support their use is flimsy at best. She calls on physician–researchers to take a collective stand and demand disclosure of all data.
In a related commentary, Herxheimer and Mintzes point to flawed trial design, secrecy in the approvals process and inadequate systems for adverse drug reporting as the mechanisms by which ineffective and unsafe drugs gain a place in the market.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
People are like stained-glass windows. They sparkle and shine when the sun is out, but when the darkness sets in, their true beauty is revealed only if there is a light from within.
-- Elizabeth Kubler-Ross